Fierce Pharma

Fierce Pharma Asia—China biotech deal spree rolls on; Shionogi buys Tanabe’s ALS business

In the past three weeks, a flurry of licensing deals with Chinese biotechs were announced featuring AbbVie, AstraZeneca, ...
Fierce Pharma

Lilly touts promise of Zepbound-Taltz combo in patients with obesity and psoriatic arthritis

In an open-label phase 3b trial, the co-administration of Lilly’s IL-17A antagonist Taltz (ixekizumab) and dual GIP/GLP-1 ...
Fierce Pharma

Vanda's shares drop after 2nd FDA rejection for Hetlioz in jet lag disorder

Less than two weeks ago, Vanda scored an FDA approval for motion sickness pill Nereus. The decision came 15 months after the ...
Fierce Pharma

InflaRx to prune headcount by 30%, curb COVID drug spending in bid to advance new favorite asset izicopan

InflaRx had been pursuing development of vilobelimab in other indications beyond COVID, but the company’s hopes for the asset ...
Fierce Pharma

AZ taps Spain head Rick Suarez to lead US biopharma unit, head up $50B investment surge

As AstraZeneca floods money into the U.S. market with a wide-ranging investment plan, the company has tapped an in-house executive to lead the surge. | Suarez will return to the U.S. as SVP and ...